clinical trial · NCT04617054
Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
Solid TumorAB-106
brief summary
AB-106 will be administered once a day. Each treatment cycle is defined as 21 days of continuous medication. Dosing will continue until any of the following conditions are met: disease progression, intolerable drug-related adverse events, researchers recommend discontinuation of treatment, withdrawal of informed consent, pregnancy during the study, use of other anti-tumor therapy, loss of follow-up, death and other causes, whichever occurs first. The study includes a screening period, treatment period, safety follow-up and long-term follow-up.
started
Jun 1, 2021
primary completion
Dec 6, 2024
completion
Dec 6, 2024
last updated
Jan 21, 2026
official title
A Phase II, Multicenter, Open, Basket Study of AB-106 to Treat the Subjects With Local Progression or Systemic Metastasis Solid Tumors With NTRK Gene Fusion
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol